Eloxx Pharmaceuticals, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Eloxx Pharmaceuticals files Amendment No. 2 to its S-1 registration statement for a $66 million common stock and pre-funded warrant offering.
NASDAQ
Eloxx Pharmaceuticals, Inc. has filed an S-1/A amendment to its registration statement, detailing plans to offer shares of common stock and pre-funded warrants, aiming for a Nasdaq Capital Market listing.
NASDAQ
Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, is seeking to raise capital and uplist its common stock to the Nasdaq Capital Market to fund the advancement of its lead product candidate, exaluren, for rare kidney diseases.